Issue of Equity in lieu of Director fees

Aptamer Group PLC

28 January 2025

 

28 January 2025

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Issue of Equity in lieu of Director fees

Aptamer Group plc (AIM: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, today announces that it has issued 3,499,343 new ordinary shares of 0.1 pence each ("Ordinary Shares") at an average issue price of 0.2858 pence per Ordinary Share to settle Non-Executive Director fees.

Director fee shares

Tim Sykes has agreed to take his Non-Executive Director fees in shares commencing 1 January 2025. Shares will be issued to Tim on a quarterly basis in lieu of fees. Today's share issue will cover the period 1 January 2025 to 31 March 2025. Each quarter, the price of each share issue will be based on the volume weighted average daily closing share price of the preceding quarter. For this share issue, that was the period 1 October 2024 to 31 December 2024.

Following this transaction, Tim Sykes total beneficial interest in the Company is 8,671,063 Ordinary Shares, representing approximately 0.44% of the Company's issued share capital.

Total voting rights

Application will be made for the admission of these shares to trading on AIM, which is expected to become effective on or about 3 February 2025.

Immediately following Admission the Company will have 1,991,343,016 Ordinary Shares of £0.001 each in issue. The Company does not hold any shares in treasury and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules.

Additional information

The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation and provide detail in relation to the purchase of Ordinary Shares by Directors and other PDMRs in the Company.

NOTIFICATIONS AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Tim Sykes
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Aptamer Group plc
b)	LEI	213800Y4XGH3WJNBE686
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.001 each
	Identification code	GB00BNRRP542
b)	Nature of the transaction	Award of shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 0.2858p 3,499,343
d)	Aggregated information
	- Aggregated volume	3,499,343
	- Price	0.2858p each
e)	Date of the transaction	28 January 2025
f)	Place of the transaction	Off market

- Ends -

For further information, please contact:

Aptamer Group plc Arron Tolley, Chief Executive Officer	[phone]
SPARK Advisory Partners Limited - Nominated Adviser   Andrew Emmott / Jade Bayat	[phone]
Turner Pope Investments (TPI) Limited - Broker   James Pope / Andrew Thacker	[phone]
Northstar Communications Limited - Investor Relations Sarah Hollins	[phone]

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.

About Aptamer Group plc 

Aptamer Group is a leading global developer of aptamer-based ligands that help scientists remove the limits to discovery and innovation. Leveraging a proprietary discovery and development platform, Aptamer delivers custom affinity ligands, supported with a complete suite of characterisation and validatory assays that enhance the translation of its binders and optimise scientific outcomes for customers.

Aptamer's cutting-edge technology spans healthcare, research, personal care, and industrial processes, delivering new affinity solutions for novel targets, advanced diagnostics, and precision therapies. By working with industry leaders in pharmaceutical, biotechnology, personal health, academic, and clinical research sectors, Aptamer is accelerating science through the custom development of tools and therapies.

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/.

 

END